Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast
Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast
Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Thyreoidea<strong>cancer</strong> – <strong>udkast</strong> <strong>Kliniske</strong> <strong>retningslinier</strong> – revision – juni <strong>2009</strong><br />
86. Hales NW, Krempl GA, Medina JE. Is there a role <strong>for</strong> fluorodeoxyglucose positron emission tomography/computed<br />
tomography in cytologically indeterminate thyroid nodules? Am.J.Otolaryngol.<br />
2008;29:113-8.<br />
87. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value<br />
of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent<br />
well-differentiated thyroid carcinoma. Ann.Surg. 2001;234:804-11.<br />
88. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L et al. Role of 18F-FDG-PET and<br />
PET/CT imaging in thyroid <strong>cancer</strong>. Biomed.Pharmacother. 2006;60:409-13.<br />
89. Mirallie E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C et al. Therapeutic impact of 18FDG-<br />
PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery<br />
2007;142:952-8.<br />
90. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined<br />
[18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT)<br />
<strong>for</strong> detection of recurrent, 131I-negative thyroid <strong>cancer</strong>. Ann.Surg.Oncol. 2008;15:286-92.<br />
91. Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A et al. Nuclear medicine procedures<br />
in the diagnosis and therapy of medullary thyroid carcinoma. Biomed.Pharmacother. 2008;62:139-46.<br />
92. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA et al. A prognostic index <strong>for</strong> thyroid<br />
carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur.J.Cancer 1979;15:1033-<br />
41.<br />
93. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery<br />
1988;104:947-53.<br />
94. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection<br />
in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic<br />
scoring system. Surgery 1987;102:1088-95.<br />
95. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary<br />
thyroid carcinoma. J.Clin.Endocrinol.Metab 1990;71:414-24.<br />
96. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid<br />
carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically<br />
treated at one institution during 1940 through 1989. Surgery 1993;114:1050-7.<br />
97. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer<br />
1993;72:2680-5.<br />
98. Randolph GW. Surgery of the thyroid and parathyroid glands. Sunders, Elsvier, 2003.<br />
99. Shaha A. Treatment of thyroid <strong>cancer</strong> based on risk groups. J.Surg.Oncol. 2006;94:683-91.<br />
100. Sampson RJ, Oka H, Key CR, Buncher CR, Iijima S. Metastases from occult thyroid carcinoma. An<br />
autopsy study from Hiroshima and Nagasaki, Japan. Cancer 1970;25:803-11.<br />
101. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno BG, Caillou B et al. Microcarcinoma of the thyroid<br />
gland: the Gustave-Roussy Institute experience [see comments]. Cancer 1998;83:553-9.<br />
102. Yamashita H, Noguchi S, Murakami N, Mochizuki Y, Nakayama I. Prognosis of minute carcinoma of<br />
thyroid. Follow-up study of 49 patients. Acta Pathol.Jpn. 1986;36:1469-75.<br />
58
Change language